Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Sees Significant Growth in Short Interest

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 119,500 shares, a growth of 70.5% from the March 15th total of 70,100 shares. Based on an average daily volume of 76,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 17.4% of the shares of the stock are sold short.

Qualigen Therapeutics Stock Performance

Shares of Qualigen Therapeutics stock traded down $0.10 during trading hours on Thursday, reaching $3.21. The company’s stock had a trading volume of 75,420 shares, compared to its average volume of 108,951. Qualigen Therapeutics has a one year low of $2.85 and a one year high of $29.44. The firm has a 50 day moving average price of $3.27 and a 200-day moving average price of $4.42.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.